Milica Radisic

The program will consider AI-related proposals. And there are also possibilities to draw expertise of NRC’s Research Centers. 

1

The Pandemic was a real education to Canada, and it's reliance on technologies and companies outside this country. When push came to shove, and the world was competitng for valuable resources to test for Covid, Canada was left out in the cold (literally). We had no access to extraction technologies, and no vaccine capabilities ourselves. DMark Biosciences played a pivotal role in supplying Canada with RNA extraction instrumentation and kits. Our partners of Revvity, MolGen, and Complete Genomics provided instrumentation and kits throughout Canada, where traditional suppliers refused to sell to Canada. Now that Canada is gearing up its vaccine response for the next pandemic, @DMark is here to help again. We have partnered with L7 Informatics for over a decade providing the best Enterprise Science platform available on the planet to manage the data required to enable biomanufacturing. This webinar will help you learn how L7/ESP will speed the time to market for Drugs from development to commercialization, Reduce costs and improve operational efficiencies, and provide a single source of truth for scientific data and process management throughout the product lifecycle management. Whether your field is protein, genomics, multi-omics, research, diagnostics, development or manufacturing, L7 will provide huge value for your scientific life sciences data management.

16

3 Comments

Congratulations to Barrow professor Rita Sattler, PhD, MSc, and her collaborators on receiving a competitive Target ALS Basic Biology Consortia Grant for a project aimed at understanding how TDP-43 dysfunction in glia contributes to #amyotrophiclateralsclerosis (ALS). In 97% of ALS cases, the TDP-43 protein moves from its normal place in the nucleus of cells to the cytoplasm, where it aggregates and affects cell function. Typically, this pathology is studied in neurons. By understanding how TDP-43 dysfunction in the non-neuronal support cells in the #brain contributes to ALS, the consortium hopes to find new ways to treat the disease that can be applied to the 97% of #ALS cases where TDP-43 is affected. Dr. Sattler's collaborators include Dr. Yuna Ayala of Saint Louis University, Dr. Christopher Donnelly of the University of Pittsburgh, Dr. Patrick Pirrotte of TGen - Part of City of Hope, and Dr. Kendall Van Keuren-Jensen of the National Institute on Aging (NIA). Their consortia was one of six that received funding out of applications submitted by 106 scientists from 76 institutions in 13 countries. Learn more about this grant: https://bar.rw/3WrXNzP

45

5 Comments

Hi everyone. As some of you know, I answer emails all day. However, the remarkably talented students in our humble lab at McMaster University work diligently to invent new antibiotics that can address the most challenging bacterial pathogens in the world. Indeed, one of the defining goals of our group is to develop meaningful and enduring solutions to the antibiotic resistance crisis. I will be 50 years old in 2039. What a fantastic way to celebrate if we had this problem solved, or very nearly so, by then. At least for the next century or two. But developing solutions to such Grand Challenges takes a lot of people from a lot of different backgrounds all rowing in the same direction. The Stokes lab is partnered with Hewlett Packard Enterprise to accelerate the development and large-scale implementation of our AI-driven molecular property prediction and molecular design algorithms for new antibiotic discovery tasks. This matters because it gets us (the collective us) another step closer to discovering and developing new antibiotics efficiently and inexpensively. If we do this right (and some other pieces fall into place...stay tuned for my thoughts in a bit) it might get us to the point where we can invent new antibiotics faster than resistance evolves, enabling us to remain just ahead of superbugs. So, we know how to discover antibiotics and they know how to build supercomputers. It's like macaroni and cheese, Ben and Jerry, rock and roll. You get the idea. Pretty rad, in my opinion. Have a read about some of our recent work below. Go to www.thebestlabever.com to read about everything else we do. Talk soon. Jon https://lnkd.in/gi7rkvtE

159

5 Comments

Last week, we convened our inaugural face-to-face YCharOS meeting, bringing together representatives from Canadian funding agencies, antibody manufacturers, pharmaceutical companies, and academia at McGill University. The objective of the meeting was to strategize how to scale this academic initiative from testing antibodies for 100 proteins to the human proteome. Through panel discussions, reverse brainstorming (thanks Hannah C. – but is it typical to fill up the entire whiteboard in few minutes with potential future problems 😉), and various presentations, we identified several potential strategies that will require a few more weeks to digest. We'll provide a summary of the meeting along with our forward strategy. A big thank you to our antibody manufacturer partners—abcam, ABclonal Technology, Aviva Systems Biology,Bio-Techne, ABCD Antibodies, Cell Signaling Technology (CST), DSHB, GeneTex, Inc., Institute for Protein Innovation, Proteintech Group, Synaptic Systems GmbH, Thermo Fisher Scientific, YCharOS Inc. —for making the YCharOS project possible and for attending the meeting. Who can guess the type of IgG represented in that picture?

89

2 Comments

𝐒𝐨𝐦𝐞 𝐑𝐞𝐜𝐞𝐧𝐭 𝐃𝐞𝐚𝐥, 𝐌&𝐀 𝐚𝐧𝐝 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐀𝐜𝐭𝐢𝐯𝐢𝐭𝐲 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐏𝐚𝐬𝐭 𝐓𝐰𝐨 𝐖𝐞𝐞𝐤𝐬: BIOVECTRA 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝘀 𝘁𝗵𝗲 𝗺𝗲𝗿𝗴𝗲𝗿 𝘄𝗶𝘁𝗵 Agilent Technologies (𝗗𝗲𝗮𝗹 𝗩𝗮𝗹𝘂𝗲: $𝟵𝟮𝟱 𝗺𝗶𝗹𝗹𝗶𝗼𝗻) Biovectra is a leading CDMO based primarily out of Canada and has been owned by HIG Capital since 2019. Team there seems to have done a great job to grow and scale that business over the past 5 years. Minaris Regenerative Medicine 𝗶𝘀 𝗮𝗰𝗾𝘂𝗶𝗿𝗲𝗱 𝗯𝘆 Altaris, LLC (𝗗𝗲𝗮𝗹 𝗩𝗮𝗹𝘂𝗲: 𝗨𝗻𝗱𝗶𝘀𝗰𝗹𝗼𝘀𝗲𝗱) Minaris, previously Hitachi ATS and prior to that PCT founded by Robert Preti in the late 90s. Actually one of the first Cell & Gene Therapy CDMOs - a move that helps Altaris move further into the CGT space. Dermavant Sciences 𝗮𝗰𝗾𝘂𝗶𝗿𝗲𝗱 𝗯𝘆 Organon (𝗗𝗲𝗮𝗹 𝗩𝗮𝗹𝘂𝗲: $𝟭.𝟮 𝗯𝗶𝗹𝗹𝗶𝗼𝗻) Dermavant, focused on developing and commercialising innovative therapeutics in dermatology, has been acquired by Organon. This acquisition seems to align nicely with their overall mission to meet unmet needs in skin health. Bain Capital 𝗜𝗻𝘃𝗲𝘀𝘁𝘀 $𝟮𝟬𝟬 𝗠𝗶𝗹𝗹𝗶𝗼𝗻 𝗶𝗻𝘁𝗼 Serán BioScience Although not the Primary investor, Bain Capital has invested $200 million into Seran to support the build a new commercial facility in Bend, Oregon. Vivo Capital remains the majority shareholder of Seran. #Investment #LifeSciences #Insights

20

2 Comments

As Reverb Therapeutics grows, we learn more about the intricacies of redirecting endogenous cytokines and the huge advantages. We now have a lab to follow up on those hypotheses. Looking forward to the next steps!

89

8 Comments